Humacyte Innovative Research in Coronary Bypass and Vascular Regeneration to be Highlighted at American Heart Association Scientific Sessions 2026
Globe Newswire•03/11/2026•08:00 ET
0
Key Highlights
- ➤Humacyte (HUMA) to present coronary tissue engineered vessel data at AHA Scientific Sessions 2026
- ➤Three presentations include Phase 2a CTEV study design and preclinical CABG results
- ➤First-in-human Phase 2a study design targets bioengineered coronary artery bypass grafting
- ➤CTEV remains investigational and lacks FDA or other regulatory approval
- ➤FDA approved Humacyte’s ATEV BLA for vascular trauma in December 2024
Expert Statements
Laura E. Niklason, Founder, President and CEO of Humacyte, Inc.
“AHA brings together the cardiac surgeons and cardiologists who will ultimately decide whether an off-the-shelf conduit belongs in bypass surgery, and we are excited for them to see our preclinical data and our study design firsthand.”
Laura E. Niklason, Founder, President and CEO of Humacyte, Inc.
“Our approach is built on the idea that the body can repopulate an engineered vessel with a patient’s own cells.”
Laura E. Niklason, Founder, President and CEO of Humacyte, Inc.
“With the CTEV, we are taking the next step toward bringing bioengineered vascular technology to coronary bypass surgery through the first U.S. clinical trial of a bioengineered CABG conduit.”
– Founder & CEO Laura Niklason, M.D., Ph.D., to deliver invited talk on engineering the microenvironment to accelerate vascular regeneration.
– Two additional presentations to cover first-in-human Phase 2a study design and preclinical results for Humacyte’s investigational coronary tissue engineered vessel.
Get started
Create a free account to read the full story.